|Last Updated: Nov 2, 2013 - 11:52:55 AM
Chromosome 21 abnormality tells oncologists to treat pediatric ALL more aggressively
A recent study by members of the Children's Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment for Acute Lymphoblastic Leukemia (ALL) than children without this gene amplification.
Aug 20, 2013 - 4:00:00 AM
Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award
The American Society of Hematology (ASH) will present the Society's highest honor, the 2013 Wallace H. Coulter Award for Lifetime Achievement in Hematology, to Professor Sir David Weatherall, MD, of the University of Oxford for his more than 50-year career in hematology combining seminal discoveries, visionary translational research leadership, and a passion for global health initiatives that have together helped improve clinical care for thousands throughout the developing world.
Aug 1, 2013 - 4:00:00 AM
Dr. John Eng to receive Golden Goose Award
The creators of the Golden Goose Award announced today that the next award will go to Dr. John Eng, a medical researcher and practicing physician whose study of the extremely poisonous venom produced by the Gila monster led to a drug that protects millions of diabetics from such complications as blindness, kidney failure, and nerve damage.
Jul 30, 2013 - 4:00:00 AM
Could sleeping stem cells hold key to treatment of aggressive blood cancer?
Scientists studying an aggressive form of leukaemia have discovered that rather than displacing healthy stem cells in the bone marrow as previously believed, the cancer is putting them to sleep to prevent them forming new blood cells.
Jul 29, 2013 - 4:00:00 AM
Stem cells enable personalised treatment for bleeding disorder
Scientists have shed light on a common bleeding disorder by growing and analysing stem cells from patients' blood to discover the cause of the disease in individual patients.
Apr 5, 2013 - 4:00:00 AM
Treatment with clot-busting drug yields better results after stroke than supportive therapy alone
In an update to previous research, Johns Hopkins neurologists say minimally invasive delivery of the drug tPA directly into potentially lethal blood clots in the brain helped more patients function independently a year after suffering an intracerebral hemorrhage (ICH), a deadly and debilitating form of stroke. Rates of functional recovery with the active tPA treatment far surpassed those achieved with standard supportive therapy that essentially gives clots a chance to shrink on their own.
Feb 7, 2013 - 5:00:00 AM
1 of the key circuits in regulating genes involved in producing blood stem cells is deciphered
Researchers from the group on stem cells and cancer at IMIM (Hospital del Mar Medical Research Institute) have deciphered one of the gene regulation circuits which would make it possible to generate hematopoietic blood cells, i.e. blood tissue stem cells. This finding is essential to generate these cells in a laboratory in the future, a therapy that could benefit patients with leukaemia or other diseases who need a transplant and who, in many cases, do not have a compatible donor.
Jan 31, 2013 - 5:00:00 AM
Blood test predicts breast cancer recurrence
London, Jan 20 - A simple blood test could tell whether the commonest form of breast cancer will recur post therapy, sparing women unwanted treatment with anti-cancer drugs.
Jan 20, 2013 - 7:22:02 PM
More than a third of high-risk leukemia patients respond to an experimental new drug
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Many of the participants who did well with the new drug, quizartinib or AC220, had failed to respond to prior therapies.
Dec 9, 2012 - 5:00:00 AM
Pre-clinical data shows Angiocidin effective against leukemia
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012 - 5:00:00 AM
$9 million to investigate blood-clotting disorders
Researchers at Washington University School of Medicine in St. Louis have received a $9 million grant to investigate blood-clotting disorders. From heart attacks and strokes to uncontrolled bleeding, clotting disorders cause more deaths each year in the United States than all types of cancer combined.
Nov 7, 2012 - 5:00:00 AM
Federal government renews contract for collecting and maintaining national stem cell transplantation database
The Medical College of Wisconsin (MCW) Center for International Blood and Marrow Transplant Research (CIBMTR) successfully competed for, and was awarded, renewal of the Stem Cell Therapeutics Outcomes Database contract with the U.S. Health Resources and Services Administration (HRSA). The CIBMTR administers the database as a key component of the national hematopoietic cell transplantation program. Hematopoietic stem cells are the cells responsible for continual regeneration of circulating blood cells throughout life; they are not embryonic stem cells.
Nov 1, 2012 - 4:00:00 AM
'Half-match' bone marrow transplants wipe out sickle cell disease in selected patients
In a preliminary clinical trial, investigators at Johns Hopkins have shown that even partially-matched bone marrow transplants can eliminate sickle cell disease in some patients, ridding them of painful and debilitating symptoms, and the need for a lifetime of pain medications and blood transfusions. The researchers say the use of such marrow could potentially help make bone marrow transplants accessible to a majority of sickle cell patients who need them.
Sep 20, 2012 - 4:00:00 AM
ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
The Ernest Beutler Lecture and Prize, named for the late Ernest Beutler, MD, a past president of ASH and physician-scientist for more than 50 years, is a two-part lectureship that recognizes major translational advances related to a single topic. This award honors two individuals, one who has enabled advances in basic science and another for achievements in clinical science or translational research.
Aug 27, 2012 - 4:00:00 AM
ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
Dr. Ley will present his lecture, The AML Genome, at 9:00 a.m. on Monday, December 10, 2012, at the 54th ASH Annual Meeting and Exposition in Atlanta. His lecture will explore the use of whole genome sequencing in AML, which has offered an unprecedented view of the mutations that cause this disease. His lecture will also focus on next-generation DNA sequencing approaches in AML that are providing detailed information about the clonal architecture of AML at presentation and its evolution at relapse, as well as new clues regarding the genetic underpinnings of drug resistance and disease progression.
Aug 27, 2012 - 4:00:00 AM
Elusive platelet count and limb development gene discovered
Researchers have identified an elusive gene responsible for Thrombocytopenia with Absent Radii (TAR), a rare inherited blood and skeletal disorder. As a result, this research is now being transformed into a medical test that allows prenatal diagnosis and genetic counselling in affected families.
Feb 26, 2012 - 5:00:00 AM
Researchers uncover gene associated with blood cancers
A genomic study of chronic blood cancer - a precursor to leukaemia - has discovered gene mutations that could enable diagnosis using only a blood test, avoiding the need for an invasive and painful bone marrow biopsy.
Sep 26, 2011 - 4:00:00 AM
New approach to thyroid surgery eliminates neck scar
CHICAGO- As the rate of thyroid cancer continues to climb, doctors are urging patients to be more cautious about thyroid nodules, a common disorder that is responsible for a small but growing number of thyroid cancer cases. Thyroid nodules affect nearly 13 million Americans and are a result of abnormal cell growth on the gland. Until recently, the only way to remove nodules and rule out cancer was through surgery that required a five centimeter incision across the front of the neck. The procedure, and the large scar that resulted, was a deterrent for many patients who feared altering their appearance for something that may not be life threatening. Today however, a new option exists that allows surgeons to access the neck through the armpit, allowing for a biopsy of tissue with no visible scar.
Aug 9, 2011 - 4:00:00 AM
Anglo-French team discover elusive gene that makes platelets gray
Researchers have identified an elusive gene responsible for Gray Platelet Syndrome, an extremely rare blood disorder in which only about 50 known cases have been reported. As a result, it is hoped that future cases will be easier to diagnose with a DNA test.
Jul 25, 2011 - 4:00:00 AM
The gene processes that drive acute myeloid leukaemia
Researchers have described how the most common gene mutation found in acute myeloid leukaemia starts the process of cancer development and how it can cooperate with a well-defined group of other mutations to cause full-blown leukaemia.
Mar 27, 2011 - 4:00:00 AM
Nationwide Children's Hospital awarded $11.5 million contract extension for biospecimen banking
Nationwide Children's Hospital was awarded $11.5 million from the National Cancer Institute (NCI) late last year to continue its role as one of two Biospecimen Core Resources (BCR) for The Cancer Genome Atlas (TCGA). Contract awards to Nationwide Children's could total up to $49.2 million over six years.
Jan 11, 2011 - 5:00:00 AM
Particles created which may help in the development of synthetic blood
University of North Carolina at Chapel Hill researchers used technology known as PRINT (Particle Replication in Non-wetting Templates) to produce very soft hydrogel particles that mimic the size, shape and flexibility of red blood cells, allowing the particles to circulate in the body for extended periods of time.
Jan 10, 2011 - 8:44:51 PM
2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients
Monthly blood transfusions combined with daily medication to remove the resulting excess iron remains the best approach for reducing the risk of recurrent strokes in young patients with sickle cell anemia, according to a preliminary analysis of a multicenter trial that includes St. Jude Children's Research Hospital.
Dec 6, 2010 - 5:00:00 AM
Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.
Dec 6, 2010 - 5:00:00 AM
Mathematical model of the life cycle of red blood cells may predict risk of anemia
A collaboration between a physician-researcher at Massachusetts General Hospital (MGH) and a mathematician from Harvard University has led to development of a mathematical model reflecting how red blood cells change in size and hemoglobin content during their four-month lifespan. In their report published online in PNAS Early Edition, John Higgins, MD, MGH Center for Systems Biology and Department of Pathology, and L. Mahadevan, PhD, Harvard School of Engineering and Applied Sciences (SEAS), also describe how their model may be used to provide valuable clinical information.
Nov 12, 2010 - 5:00:00 AM
Key to blood-brain barrier opens way for treating Alzheimer's and stroke
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Oct 14, 2010 - 4:00:00 AM
Filtering donor blood reduces heart, lung complications
Researchers at the University of Rochester Medical Center (URMC) have discovered yet another reason to filter the foreign white cells from donor blood: The resulting blood product is associated with dramatically fewer cardiopulmonary complications for patients who received a transfusion.
Jun 22, 2010 - 4:00:00 AM
NHLBI funds research to improve safety of red blood cell transfusions
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is funding nine research grants to determine if the safety and efficacy of red blood cell transfusions vary depending on how long the cells have been stored. One of the grants supports the first large, multi-center, randomized clinical trial to compare outcomes in heart surgery patients who receive transfusions of red blood cells that have been stored for shorter or longer amounts of time. The other eight research grants provide about $3.9 million per year over four years to assess the safety and efficacy of red blood cell transfusions.
Jun 21, 2010 - 4:00:00 AM
Stroke prevention study in children with sickle cell anemia, iron overload stopped early
The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.
Jun 4, 2010 - 4:00:00 AM
NHLBI, CDC launch surveillance and research program for inherited blood diseases
Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.
Feb 18, 2010 - 5:00:00 AM
Researchers revisit pulmonary arterial hypertension survival
Setting out to determine the survival of patients with pulmonary arterial hypertension (PAH), researchers at the University of Chicago Medical Center and their colleagues also discovered that an equation used for more than 20 years to predict survival is outdated. Accordingly, they developed and recently published a new survival prediction equation that will impact clinical practice and the drug development process.
Jan 6, 2010 - 4:59:36 AM
H1N1 more risky than seasonal flu in children with sickle cell disease
Infection with the H1N1 virus, or swine flu, causes more life-threatening complications than seasonal flu in children with sickle cell disease, according to research from Johns Hopkins Children's Center. The findings, to be presented on Dec. 7 at the annual meeting of the American Society of Hematology, warn parents and caregivers that such children are more likely to need emergency treatment and stays in an intensive-care unit.
Dec 7, 2009 - 5:00:00 AM
Vital discovery may save many from traumatic deaths
Researchers have unravelled how certain proteins can enter the bloodstream and begin to kill the lining of blood vessels, resulting in uncontrolled internal bleeding. Their discovery could help save thousands from traumatic deaths, caused by car crashes or on the battlefield.
Nov 5, 2009 - 3:06:44 PM
The American Society of Hematology to honor inspirational hematologists with Mentor Awards
(WASHINGTON, November 3, 2009) - The American Society of Hematology (ASH) is honoring two prominent hematologists with ASH Mentor Awards in recognition of the important role they play in the training and career development of hematologists early in their careers. Stuart H. Orkin, MD, and Arthur W. Nienhuis, MD, will receive their awards during the 51st ASH Annual Meeting in New Orleans.
Nov 3, 2009 - 5:00:00 AM
Transfusions Risky For Cardiac Patients
Blood transfusion to hospitalised cardiac patients doubles the risk of infection and quadruples the risk of death, according to a new study.
Aug 8, 2009 - 1:45:47 PM
NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns. In an interim review of safety data from 33 participants who completed 16 weeks of treatment, researchers found that, compared to participants on placebo (dummy pill), participants taking sildenafil (Revatio) were significantly more likely to have serious medical problems. The most common problem was episodes of severe pain called sickle cell crises, which resulted in hospitalization. No deaths have been associated with the drug in the clinical trial.
Jul 28, 2009 - 4:00:00 AM
Anemia linked with higher death risk in heart patients
The presence of anaemia in patients with chronic heart failure is linked to a significantly higher risk of death.
Jun 18, 2009 - 3:42:28 PM
Common chemotherapy drug triggers fatal allergic reactions
CHICAGO -- A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.
Jun 8, 2009 - 4:00:00 AM
Canadian biomedical engineering pioneer receives international award
Countless individuals around the world are alive because of him. His 40 plus years of research have helped to make the use of life-saving devices such as prosthetic heart valves, vascular stents, vascular grafts, heart-assist devices, and heart-lung bypass systems almost commonplace. In the process, he has helped to establish Canada as a biomaterials leader.
Apr 23, 2009 - 4:00:00 AM
Potential breakthrough for T-Cell lymphoma patients with drug that mimics folic acid
NEW YORK (Dec. 8, 2008) -- Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL). PROPEL (Pralatrexate in patients with Relapsed Or refractory PEripheral T-cell Lymphoma) findings were presented by the study's principal investigator, Dr. Owen A. O'Connor of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital, at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
Dec 9, 2008 - 5:00:00 AM
Bone marrow stem cell niche discovered
Researchers have identified the precise location of the bone marrow stem cell niche.
Dec 7, 2008 - 5:36:33 PM
Transcranial Doppler ultrasonography screening helps in preventing strokes in children with sickle cell disease
Screening with an ultrasound machine has proved highly successful in preventing stroke among children with sickle cell disease, by identifying children who are then preventively treated with blood transfusions. Over an eight-year period at The Children's Hospital of Philadelphia, researchers found that the technique, transcranial Doppler ultrasonography (TCD), along with regular transfusions for children found to be at high risk, reduced stroke to one-tenth of the incidence found before TCD was introduced.
Dec 7, 2008 - 2:10:44 PM
Evaluation of new anti-coagulant drugs
The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy was presented in a press conference during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research featured at the press conference includes studies that examine the use of three different investigational blood-thinning medications that belong to a new class of therapies called Factor Xa inhibitors.
Dec 7, 2008 - 2:02:09 PM
Researchers aim to over-stress already taxed mantle cell lymphoma cells
AUGUSTA, Ga. - Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.
Nov 10, 2008 - 5:00:00 AM
'Old blood' linked to infection
Blood stored for 29 days or more, nearly 2 weeks less than the current standard for blood storage, is associated with a higher infection rate in patients who received transfusions with the blood. In a new study presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians (ACCP), researchers found that patients who received transfusions with blood stored for 29 days or more were twice as likely to suffer from nosocomial infections, including pneumonia, upper respiratory infections, and sepsis, with the oldest blood being associated with the most infections. Currently, federal regulations allow red blood cells to be stored up to 42 days, after which they must be discarded.
Oct 28, 2008 - 4:00:00 AM
Einstein and Montefiore receive grants to expand disease-focused stem cell research
The Empire State Stem Cell Board has awarded research planning grants to Albert Einstein College of Medicine and to Montefiore Medical Center. The grants, totaling $238,000, are part of $2 million in grants announced by State Health Commissioner Richard F. Daines, M.D. The funding, awarded to 18 medical colleges, medical centers and labs will strengthen New York State's capacity for stem cell research and could lead to the development of new therapies for Alzheimer's, diabetes, Parkinson's, ALS and other conditions.
Oct 3, 2008 - 4:00:00 AM
High blood pressure takes big toll on small filtering units of the kidney
Take a kidney out of the body and it still knows how to filter toxins from the blood.
Sep 19, 2008 - 4:00:00 AM
Better understanding of blood vessel constrictor needed to harness its power for patients
To harness endothelin-1's power to constrict blood vessels and help patients manage high blood pressure or heart failure, scientists must learn more about how endothelin functions naturally and in disease states, says a Medical College of Georgia researcher.
Sep 18, 2008 - 4:00:00 AM
'Cancer was one of the best things to happen to me... but I worry about the future'
London, UK: For Dan Savage, surviving testicular cancer has been a spur to him making the most of his life and taking more adventurous decisions, and he says, that in retrospect, it was probably one of the best things that has happened to him. But as he approaches the end of his fifth year in remission from the disease, when he will be signed off as cured by the medical profession, he worries that from now on he will have no regular medical checks that might pick up early signs of the cancer returning. It will be down to him to contact the cancer clinic if he is worried about any new symptoms.
Jun 10, 2008 - 4:00:00 AM
Cancer incidence and mortality in young people decreases with increasing deprivation
London, UK: Results of research into the associations between cancer and socio-economic deprivation and affluence have shown that, in contrast to cancers in older people, the numbers of new cases and deaths from the disease in teenagers and young adults (TYAs) decrease with increasing deprivation.
Jun 9, 2008 - 4:00:00 AM